Cancer Drug Discovery and Development
Jeffrey S. Humphrey, Joseph G. Naglich, John Bird, Daryl Sonnichsen, Andrew Baxter, Karen Price(Purchase College), Elora Gupta
Cited by 194
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection
|American Journal of Transplantation|2017|96
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
|Journal of Autoimmunity|2020|79
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies
|Analytical and Bioanalytical Chemistry|2011|63